Nurix Therapeutics (NRIX) Receivables (2021 - 2025)

Nurix Therapeutics (NRIX) has 5 years of Receivables data on file, last reported at $20.7 million in Q2 2025.

• Receivables for Q2 2025 came in at $20.7 million, changed N/A year-over-year; the trailing twelve-month figure through May 2025 was $20.7 million (changed N/A YoY), and the FY2024 annual result was $5.0 million, changed N/A from the prior year.
• Receivables climbed to $20.7 million in Q2 2025 per NRIX's latest filing, from $5.0 million in the prior quarter.
• Over five years, Receivables peaked at $20.7 million in Q2 2025 and troughed at $906000.0 in Q1 2022.
• A 5-year average of $6.4 million and a median of $5.0 million in 2024 frame the typical range for Receivables.
• On a YoY basis, Receivables climbed as much as 85.51% in 2022 and fell as far as 85.51% in 2022.
• A 5-year view of Receivables shows it stood at $6.9 million in 2021, then tumbled by 85.51% to $1.0 million in 2022, then soared by 700.0% to $8.0 million in 2023, then tumbled by 37.5% to $5.0 million in 2024, then jumped by 314.0% to $20.7 million in 2025.
• Business Quant data shows NRIX's Receivables at $20.7 million in Q2 2025, $5.0 million in Q4 2024, and $8.0 million in Q3 2023.